A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Adjustable Lens Customizable After Cataract Surgery Is Now Offered at Northwell Health

The latest development in cataract surgery is now available at several Northwell locations including Peconic Bay Medical Center, Syosset Surgical center and Manhattan Eye, Ear, and Throat Hospital. The cutting-edge Light Adjustable Lens (LAL) enables patients and their doctor to design, trial and customize vision after cataract surgery, more often giving patients their very best possible vision without eyeglasses after surgery.

A cataract is a cloudy area in the lens of the eye that leads to a decrease in vision. Cataracts often develop slowly and can affect one or both eyes. Symptoms may include faded colors, blurry or double vision, halos around light, trouble with bright lights, and trouble seeing at night.

“RxSight’s Light Adjustable Lens allows ophthalmologists to give cataract patients even more precise visual outcomes than ever before,” said Richard Braunstein, MD, senior vice president and executive director of ophthalmology at Northwell Health. “We’re always striving to provide the best care possible for our patients, and with this new technology we are living up to that goal.”

The intraocular lens is made of a unique material that reacts to UV light, which is delivered by the Light Delivery Device, as soon as 17 days after surgery. Patients receive three to five light treatments over a period of several weeks, each lasting about 40-150 seconds, depending upon the amount of adjustment needed. The patient must wear special eyeglasses for UV protection from the time of the cataract surgery to the end of the light treatments to protect the new lens from UV light in the environment.

“Small variations in healing happen in most eyes and with the Light Adjustable Lens, we gain the ability to correct even small amounts of nearsightedness, farsightedness and astigmatism,” said Scott Sheren, MD, director of ophthalmology at Northwell Health Eye Institute at Riverhead. “This lens is amazing because you can adjust its shape and thus its power in the eye and this is done without the use of a laser or conventional surgery.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy